Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
AtriCure Analyst Ratings and Price Targets | NASDAQ:ATRC | Benzinga
AtriCure Inc has a consensus price target of $50.55 based on the ratings of 11 analysts. The high is $60 issued by JMP Securities on April 30, 2025. The low is $40 issued by JP Morgan on October 30, 2024. The 3 most-recent analyst ratings were released by UBS, JMP Securities, and Needham on April 30, 2025, respectively. With an average price target of $54 between UBS, JMP Securities, and Needham, there's an implied 60.71% upside for AtriCure Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
UBS
JMP Securities
Needham
Citizens Capital Markets
Canaccord Genuity
1calculated from analyst ratings
Analyst Ratings for AtriCure
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/30/2025 | Buy Now | 72.62% | UBS | Danielle Antalffy60% | $60 → $58 | Maintains | Buy | Get Alert |
| 04/30/2025 | Buy Now | 78.57% | JMP Securities | Daniel Stauder47% | $60 → $60 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 04/30/2025 | Buy Now | 30.95% | Needham | Mike Matson56% | $51 → $44 | Maintains | Buy | Get Alert |
| 04/02/2025 | Buy Now | 78.57% | Citizens Capital Markets | Daniel Stauder47% | $60 → $60 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 03/28/2025 | Buy Now | 54.76% | Canaccord Genuity | William Plovanic59% | $66 → $52 | Maintains | Buy | Get Alert |
| 03/27/2025 | Buy Now | 36.9% | JP Morgan | Lilia-Celine Lozada28% | $51 → $46 | Maintains | Overweight | Get Alert |
| 03/27/2025 | Buy Now | 51.79% | Needham | Mike Matson56% | $51 → $51 | Reiterates | Buy → Buy | Get Alert |
| 03/21/2025 | Buy Now | 51.79% | Needham | Mike Matson56% | $51 → $51 | Reiterates | Buy → Buy | Get Alert |
| 02/13/2025 | Buy Now | 33.93% | Oppenheimer | Suraj Kalia58% | $36 → $45 | Maintains | Outperform | Get Alert |
| 02/13/2025 | Buy Now | 48.81% | Piper Sandler | Matt O'Brien52% | $40 → $50 | Maintains | Overweight | Get Alert |
| 02/13/2025 | Buy Now | 78.57% | JMP Securities | Daniel Stauder47% | $60 → $60 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 02/13/2025 | Buy Now | 42.86% | Stifel | Rick Wise73% | $36 → $48 | Maintains | Buy | Get Alert |
| 02/13/2025 | Buy Now | 51.79% | Needham | Mike Matson56% | $51 → $51 | Reiterates | Buy → Buy | Get Alert |
| 02/13/2025 | Buy Now | 96.43% | Canaccord Genuity | William Plovanic59% | $61 → $66 | Maintains | Buy | Get Alert |
| 02/11/2025 | Buy Now | 51.79% | JP Morgan | Lilia-Celine Lozada28% | $40 → $51 | Maintains | Overweight | Get Alert |
| 02/10/2025 | Buy Now | 78.57% | JMP Securities | Daniel Stauder47% | $60 → $60 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 01/22/2025 | Buy Now | 51.79% | Needham | Mike Matson56% | $40 → $51 | Maintains | Buy | Get Alert |
| 01/13/2025 | Buy Now | 19.05% | Needham | Mike Matson56% | $40 → $40 | Reiterates | Buy → Buy | Get Alert |
| 12/17/2024 | Buy Now | 19.05% | JP Morgan | Lilia-Celine Lozada28% | → $40 | Assumes | → Overweight | Get Alert |
| 12/09/2024 | Buy Now | 81.55% | Canaccord Genuity | William Plovanic59% | $53 → $61 | Maintains | Buy | Get Alert |
| 10/30/2024 | Buy Now | 57.74% | Canaccord Genuity | William Plovanic59% | $49 → $53 | Maintains | Buy | Get Alert |
| 10/30/2024 | Buy Now | 7.14% | Oppenheimer | Suraj Kalia58% | $32 → $36 | Maintains | Outperform | Get Alert |
| 10/30/2024 | Buy Now | 19.05% | JP Morgan | Robbie Marcus67% | $30 → $40 | Maintains | Overweight | Get Alert |
| 10/30/2024 | Buy Now | 19.05% | UBS | Danielle Antalffy60% | $35 → $40 | Maintains | Buy | Get Alert |
| 10/30/2024 | Buy Now | 19.05% | Needham | Mike Matson56% | $34 → $40 | Maintains | Buy | Get Alert |
| 07/31/2024 | Buy Now | 57.74% | BTIG | Marie Thibault63% | $58 → $53 | Maintains | Buy | Get Alert |
| 07/31/2024 | Buy Now | -10.71% | JP Morgan | Robbie Marcus67% | $34 → $30 | Maintains | Overweight | Get Alert |
| 07/31/2024 | Buy Now | -22.62% | Stifel | Rick Wise73% | $30 → $26 | Maintains | Buy | Get Alert |
| 07/31/2024 | Buy Now | 19.05% | Piper Sandler | Matt O'Brien52% | $65 → $40 | Maintains | Overweight | Get Alert |
| 07/31/2024 | Buy Now | 1.19% | Needham | Mike Matson56% | $40 → $34 | Maintains | Buy | Get Alert |
| 07/08/2024 | Buy Now | 19.05% | Needham | Mike Matson56% | $40 → $40 | Reiterates | Buy → Buy | Get Alert |
| 05/02/2024 | Buy Now | 45.83% | Canaccord Genuity | William Plovanic59% | $57 → $49 | Maintains | Buy | Get Alert |
| 05/02/2024 | Buy Now | 1.19% | JP Morgan | Robbie Marcus67% | $42 → $34 | Maintains | Overweight | Get Alert |
| 05/02/2024 | Buy Now | 19.05% | Needham | Mike Matson56% | $46 → $40 | Maintains | Buy | Get Alert |
| 04/23/2024 | Buy Now | -4.76% | Oppenheimer | Suraj Kalia58% | → $32 | Upgrade | Perform → Outperform | Get Alert |
| 04/10/2024 | Buy Now | 36.9% | Needham | Mike Matson56% | $46 → $46 | Reiterates | Buy → Buy | Get Alert |
| 02/16/2024 | Buy Now | 72.62% | UBS | Danielle Antalffy60% | $57 → $58 | Maintains | Buy | Get Alert |
| 02/16/2024 | Buy Now | 25% | Stifel | Rick Wise73% | $50 → $42 | Maintains | Buy | Get Alert |
| 02/16/2024 | Buy Now | 36.9% | Needham | Mike Matson56% | $44 → $46 | Maintains | Buy | Get Alert |
| 01/22/2024 | Buy Now | 69.64% | UBS | Danielle Antalffy60% | $56 → $57 | Maintains | Buy | Get Alert |
| 01/04/2024 | Buy Now | 30.95% | Needham | Mike Matson56% | $49 → $44 | Maintains | Buy | Get Alert |
| 11/29/2023 | Buy Now | 78.57% | JMP Securities | Daniel Stauder47% | → $60 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 11/29/2023 | Buy Now | 45.83% | Needham | Mike Matson56% | → $49 | Reiterates | Buy → Buy | Get Alert |
| 11/02/2023 | Buy Now | 48.81% | JP Morgan | Robbie Marcus67% | $60 → $50 | Maintains | Overweight | Get Alert |
| 11/02/2023 | Buy Now | 45.83% | Needham | Mike Matson56% | $68 → $49 | Maintains | Buy | Get Alert |
| 10/23/2023 | Buy Now | 78.57% | JMP Securities | Daniel Stauder47% | → $60 | Initiates | → Market Outperform | Get Alert |
| 09/29/2023 | Buy Now | 66.67% | UBS | Danielle Antalffy60% | → $56 | Initiates | → Buy | Get Alert |
| 07/26/2023 | Buy Now | 102.38% | Needham | Mike Matson56% | $60 → $68 | Maintains | Buy | Get Alert |
| 06/02/2023 | Buy Now | 78.57% | Needham | Mike Matson56% | → $60 | Reiterates | Buy → Buy | Get Alert |
| 05/03/2023 | Buy Now | 78.57% | Needham | Mike Matson56% | $58 → $60 | Maintains | Buy | Get Alert |
| 04/17/2023 | Buy Now | 72.62% | Needham | Mike Matson56% | → $58 | Maintains | Buy | Get Alert |
| 02/22/2023 | Buy Now | 63.69% | BTIG | Marie Thibault63% | $65 → $55 | Maintains | Buy | Get Alert |
| 02/22/2023 | Buy Now | 42.86% | Stifel | Rick Wise73% | $55 → $48 | Maintains | Buy | Get Alert |
| 02/22/2023 | Buy Now | 120.24% | Canaccord Genuity | William Plovanic59% | $81 → $74 | Maintains | Buy | Get Alert |
| 02/22/2023 | Buy Now | 72.62% | Needham | Mike Matson56% | → $58 | Reiterates | → Buy | Get Alert |
| 02/06/2023 | Buy Now | 141.07% | Canaccord Genuity | William Plovanic59% | $67 → $81 | Maintains | Buy | Get Alert |
| 12/19/2022 | Buy Now | 72.62% | Needham | Mike Matson56% | $55 → $58 | Maintains | Buy | Get Alert |
| 11/02/2022 | Buy Now | 93.45% | Canaccord Genuity | William Plovanic59% | $72 → $65 | Maintains | Buy | Get Alert |
| 11/02/2022 | Buy Now | 63.69% | Needham | Mike Matson56% | $65 → $55 | Maintains | Buy | Get Alert |
| 10/17/2022 | Buy Now | 111.31% | BTIG | Marie Thibault63% | $75 → $71 | Maintains | Buy | Get Alert |
| 08/03/2022 | Buy Now | 63.69% | Piper Sandler | Matt O'Brien52% | $90 → $55 | Maintains | Overweight | Get Alert |
| 08/03/2022 | Buy Now | 93.45% | Needham | Mike Matson56% | $55 → $65 | Maintains | Buy | Get Alert |
| 07/18/2022 | Buy Now | 48.81% | Stifel | Rick Wise73% | $70 → $50 | Maintains | Buy | Get Alert |
| 06/28/2022 | Buy Now | 63.69% | Needham | Mike Matson56% | $67 → $55 | Maintains | Buy | Get Alert |
| 06/24/2022 | Buy Now | 123.21% | BTIG | Marie Thibault63% | $94 → $75 | Maintains | Buy | Get Alert |
FAQ
What is the target price for AtriCure (ATRC) stock?
The latest price target for AtriCure (NASDAQ:ATRC) was reported by UBS on April 30, 2025. The analyst firm set a price target for $58.00 expecting ATRC to rise to within 12 months (a possible 72.62% upside). 31 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for AtriCure (ATRC)?
The latest analyst rating for AtriCure (NASDAQ:ATRC) was provided by UBS, and AtriCure maintained their buy rating.
When was the last upgrade for AtriCure (ATRC)?
The last upgrade for AtriCure Inc happened on April 23, 2024 when Oppenheimer raised their price target to $32. Oppenheimer previously had a perform for AtriCure Inc.
When was the last downgrade for AtriCure (ATRC)?
There is no last downgrade for AtriCure.
When is the next analyst rating going to be posted or updated for AtriCure (ATRC)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AtriCure, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AtriCure was filed on April 30, 2025 so you should expect the next rating to be made available sometime around April 30, 2026.
Is the Analyst Rating AtriCure (ATRC) correct?
While ratings are subjective and will change, the latest AtriCure (ATRC) rating was a maintained with a price target of $60.00 to $58.00. The current price AtriCure (ATRC) is trading at is $33.60, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
